Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for metastatic melanoma; the SCIB2/iSCIB2 vaccine, currently being evaluated for its effectiveness against various solid tumors, such as non-small cell lung cancer; and Modi-1, which is progressing through Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is working on Modi-2, designed to target homocitrullinated cancer antigens. The company also has SCOV1 and SCOV2 COVIDITY in its portfolio, which are DNA vaccines developed to fight the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
—
Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for metastatic melanoma; the SCIB2/iSCIB2 vaccine, currently being evaluated for its effectiveness against various solid tumors, such as non-small cell lung cancer; and Modi-1, which is progressing through Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is working on Modi-2, designed to target homocitrullinated cancer antigens. The company also has SCOV1 and SCOV2 COVIDITY in its portfolio, which are DNA vaccines developed to fight the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
—
Daily adjusted close
Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for metastatic melanoma; the SCIB2/iSCIB2 vaccine, currently being evaluated for its effectiveness against various solid tumors, such as non-small cell lung cancer; and Modi-1, which is progressing through Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is working on Modi-2, designed to target homocitrullinated cancer antigens. The company also has SCOV1 and SCOV2 COVIDITY in its portfolio, which are DNA vaccines developed to fight the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.